Use access key #2 to skip to page content.

EPS100Momentum (71.52)

FDA approval Biotech News.

Recs

6

April 07, 2011 – Comments (1) | RELATED TICKERS: GSK , XNPT

Wedbush Reiterates OP Rating, $23 PT On XNPT


By BenzingaStaffL
April 07, 2011 7:49 AM
Wedbush is reiterating its OP rating and $23 PT on shares of XenoPort, Inc. (NASDAQ: XNPT).

XenoPort closed Wednesday at $6.38.

“Our price target of $23/share is derived from a sum of the parts valuation,” Wedbush writes. “We do not include the potential for ex-U.S. royalties for any products, the $290 million in sale-based milestones for XP-13512, or the remaining pre-commercialization milestones.”


Read more: http://www.benzinga.com/analyst-ratings/11/04/985992/wedbush-reiterates-op-rating-23-pt-on-xnpt#ixzz1IrQEkf4r   About Stocks: GSK, XNPT

1 Comments – Post Your Own

#1) On April 07, 2011 at 2:47 PM, Momentum22 (28.80) wrote:

This is not my typical move but I couldn't help but take a dip in RL at 9.99.

Report this comment

Featured Broker Partners


Advertisement